<DOC>
	<DOCNO>NCT02073474</DOCNO>
	<brief_summary>The purpose registry monitor safety outcomes patient receive Sativex® Multiple Sclerosis ( MS ) spasticity off-label indication United Kingdom ( UK ) , Germany Sweden .</brief_summary>
	<brief_title>An Observational Post-Marketing Safety Registry Sativex®</brief_title>
	<detailed_description>The objective multi-centre , observational program evaluate long-term safety Sativex® special regard following : - The potential addiction , abuse misuse illegal purpose - The potential long-term psychiatric effect include suicidality psychosis - The potential mood change / psychological effect ( confusion / disorientation ) - The potential memory impairment - The effect drive ability - The potential fall - The use MS concomitant medication All physician prescribe Sativex® UK specialist neurology centre Germany Sweden invite participate registry provide information regard background objective study . The prescribe physician ask enter follow information via electronic Case Report Forms ( CRF ) 6 monthly interval 24 month one patient : Sativex® Use : - Was Sativex® prescribe Spasticity MS ? ( Yes/No ) . If , specify indication prescribe Sativex® - Year Spasticity diagnosis ( Germany/Sweden ) - Sativex® start date - Sativex® daily dose ( average , minimum maximum ) - Date last prescription - Is Sativex® provide worthwhile benefit ? ( Yes/ No/ Do n't Know ) - Has Sativex® stop permanently ? ( Yes /No ) . If yes , reason stop provide . - Sativex® stop date Adverse Events ( AE ) : - Have clinically significant adverse event report patient since start take Sativex® ( initial record ) ; clinically significant adverse event occur , ongoing , period ( follow-up record ) ( If yes , detail record AE form ) - Has patient seek medical attention fall related injury ; since start take Sativex® ( initial record ) ; period ( follow-up record ) ( If yes , detail record AE form ) - Has patient experience suicidal thought attempt suicide ; since start take Sativex® ( initial record ) ; period ( follow-up record ) ( If yes , detail record AE form ) - Has patient experience significant psychiatric psychotic event ; since start take Sativex® ( initial record ) ; period ( follow-up record ) ( If yes , detail record AE form ) - Has patient report change drive ability ; since start take Sativex® ( initial record ) ; period ( follow-up record ) - Improved - No change - Deteriorated - Not appropriate Supporting Information : - Medical History relevant adverse event - What Spasticity medications previously use stop permanently ( baclofen , tizanidine , benzodiazepine , gabapentin , botulinum toxin ) ( Germany/Sweden ) - Changes MS symptom medication ; since start take Sativex® ( initial record ) ; period ( follow-up record ) ? Survival status : - Is patient currently alive ? If , date death cause death . - Was death due suicide ( Yes/No ) Paper CRF also available subsequently enter electronic CRF database . The data Registry analyse descriptively collate summary table listing . A Registry report base upon data summary include within Periodic Safety Update Reports Sativex® result submit appropriate Regulatory Agencies within 60 day data summary table listing become available . Each six monthly report data table listing review independent Sativex® Registry Advisory Board summary overview prepared committee . A final Registry report assemble within 180 day final study data available . Any significant safety issue identify communicated relevant Regulatory Agencies immediately .</detailed_description>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Dronabinol</mesh_term>
	<criteria>All patient prescribe Sativex® UK Patients prescribe Sativex® select specialist neurology centre Germany Sweden .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>cannabinoids</keyword>
	<keyword>Sativex</keyword>
	<keyword>THC</keyword>
	<keyword>delta-9-tetrahydrocannabinol</keyword>
	<keyword>cannabidiol</keyword>
	<keyword>CBD</keyword>
	<keyword>Registry</keyword>
	<keyword>Safety</keyword>
	<keyword>MS</keyword>
</DOC>